No. |
薬物名(臨床試験情報から抽出) |
DrugBank |
KEGG DRUG * |
KEGG GENES * |
KEGG PATHWAY |
指定難病告示番号 * |
1 |
Acetate |
Acetate |
- |
- |
- |
40件: 1, 2, 6, 10, 13, 35, 40, 46, 49, 51, 60, 64, 70, 71, 73, 75, 76, 78, 81, 83, 85, 86, 88, 90, 96, 97, 113, 145, 156, 162, 171, 206, 222, 224, 225, 235, 265, 288, 298, 299 |
2 |
Alx-0081 |
- |
- |
- |
- |
1件: 64 |
3 |
Anfibatide |
Anfibatide |
- |
- |
- |
1件: 64 |
4 |
Anti-von willebrand factor nanobody |
Von willebrand factor human |
- |
- |
- |
1件: 64 |
5 |
Anti-von willebrand factor nanobody, inn = caplacizumab |
Caplacizumab |
D11160 |
1件: VWF |
6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation |
1件: 64 |
6 |
Apadamtase alfa |
Apadamtase alfa |
- |
- |
- |
1件: 64 |
7 |
Arc 1779 |
- |
- |
- |
- |
2件: 64, 288 |
8 |
Arc1779 |
- |
- |
- |
- |
2件: 64, 288 |
9 |
Arc1779 injection |
- |
- |
- |
- |
2件: 64, 288 |
10 |
Bax930 |
- |
- |
- |
- |
1件: 64 |
11 |
Bax930 or shp655 |
- |
- |
- |
- |
1件: 64 |
12 |
Caplacizumab |
Caplacizumab |
D11160 |
1件: VWF |
6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation |
1件: 64 |
13 |
Caplacizumab (alx-0081) |
Caplacizumab |
D11160 |
1件: VWF |
6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation |
1件: 64 |
14 |
Caplacizumab (an anti-von willebrand factor nanobody alx-0081) |
Caplacizumab |
D11160 |
1件: VWF |
6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation |
1件: 64 |
15 |
Caplacizumab (an anti-von willebrand factor nanobody) |
Caplacizumab |
D11160 |
1件: VWF |
6件: Complement and coagulation cascades, ECM-receptor interaction, Focal adhesion, Human papillomavirus infection, PI3K-Akt signaling pathway, Platelet activation |
1件: 64 |
16 |
Corticosteroid treatment (methylprednisolone or prednisolone) |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
1件: 64 |
17 |
Corticosteroids |
- |
- |
- |
- |
9件: 41, 46, 49, 64, 97, 164, 220, 296, 300 |
18 |
Cryosupernatant plasma |
- |
- |
- |
- |
1件: 64 |
19 |
Cyclosporine |
Ciclosporin |
D00184 |
5件: PPP3CA, PPP3CB, PPP3CC, PPP3R1, PPP3R2 |
30件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis (ALS), Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway |
33件: 11, 14, 19, 20, 28, 36, 40, 41, 42, 45, 46, 49, 50, 53, 56, 58, 60, 62, 64, 65, 90, 95, 97, 162, 164, 222, 226, 228, 234, 283, 284, 285, 302 |
20 |
Danazol |
Danazol |
D00289 |
3件: AR, ESR1, PGR |
11件: Breast cancer, Endocrine and other factor-regulated calcium reabsorption, Endocrine resistance, Estrogen signaling pathway, Oocyte meiosis, Pathways in cancer, Progesterone-mediated oocyte maturation, Prolactin signaling pathway, Prostate cancer, Proteoglycans in cancer, Thyroid hormone signaling pathway |
4件: 60, 64, 65, 285 |
21 |
Desmopressin |
Desmopressin |
D00291, D02235 |
2件: AVPR2, F8 |
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
5件: 6, 64, 72, 225, 288 |
22 |
Desmopressin acetate |
Desmopressin |
D00291, D02235 |
2件: AVPR2, F8 |
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
2件: 64, 288 |
23 |
Hmed-ides |
Imlifidase |
D11470 |
- |
- |
2件: 64, 221 |
24 |
Idec-c2b8 |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 64 |
25 |
Idec-c2b8, ro 45-2294 |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 64 |
26 |
Ides |
- |
- |
- |
- |
1件: 64 |
27 |
Ides (0.25 mg/kg) |
- |
- |
- |
- |
1件: 64 |
28 |
Ides (0.50 mg/kg) |
- |
- |
- |
- |
1件: 64 |
29 |
Immunosuppressive treatment (eg, rituximab) |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
1件: 64 |
30 |
Mabthera |
- |
- |
- |
- |
15件: 11, 13, 35, 46, 50, 51, 53, 61, 63, 64, 65, 83, 162, 222, 271 |
31 |
Magnesium |
Magnesium |
- |
- |
- |
15件: 6, 11, 13, 46, 64, 93, 97, 166, 225, 235, 284, 291, 296, 297, 298 |
32 |
Methylprednisolone |
Methylprednisolone |
D00407, D00751, D00979, D05000, D05001, D05002 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
36件: 2, 13, 25, 26, 35, 38, 39, 40, 41, 42, 43, 45, 46, 49, 50, 51, 60, 63, 64, 65, 66, 83, 84, 86, 96, 97, 145, 164, 220, 222, 224, 271, 283, 284, 285, 296 |
33 |
Minirin |
Desmopressin |
D00291, D02235 |
2件: AVPR2, F8 |
4件: Complement and coagulation cascades, Neuroactive ligand-receptor interaction, Phospholipase D signaling pathway, Vasopressin-regulated water reabsorption |
2件: 64, 288 |
34 |
Octaplas |
- |
- |
- |
- |
1件: 64 |
35 |
Octaplas infusion |
- |
- |
- |
- |
1件: 64 |
36 |
Octaplaslg® |
- |
- |
- |
- |
1件: 64 |
37 |
Octostim |
- |
- |
- |
- |
2件: 64, 288 |
38 |
Oms721 |
- |
- |
- |
- |
5件: 64, 66, 109, 222, 223 |
39 |
Oms721 100 mg/ml injection solution, oms00620646, oms620646, masp-2 antibody |
- |
- |
- |
- |
2件: 64, 109 |
40 |
Oms721 185 mg/ml injection solution, oms00620646, oms620646, masp-2 antibody |
- |
- |
- |
- |
2件: 64, 109 |
41 |
Plasma exchange (pe) |
- |
- |
- |
- |
1件: 64 |
42 |
Prednisolone |
Prednisolone |
D00472, D00980, D00981, D00982, D01239, D01998, D02156, D03301 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
38件: 11, 13, 25, 26, 35, 38, 39, 41, 43, 44, 45, 46, 49, 50, 51, 56, 60, 61, 63, 64, 65, 66, 75, 81, 84, 85, 95, 96, 97, 113, 145, 162, 222, 269, 271, 296, 299, 300 |
43 |
Prednisone |
Prednisone |
D00473 |
1件: NR3C1 |
1件: Neuroactive ligand-receptor interaction |
43件: 2, 11, 13, 14, 26, 35, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 53, 61, 63, 64, 65, 66, 81, 84, 85, 86, 95, 96, 97, 113, 162, 164, 222, 224, 228, 251, 283, 284, 285, 288, 299, 300, 331 |
44 |
Radamts-13 |
- |
- |
- |
- |
1件: 64 |
45 |
Recombinant a disintegrin and metalloproteinase with thrombospondin type-1 motifs |
- |
- |
- |
- |
1件: 64 |
46 |
Recombinant a disintegrin and metalloproteinase with thrombospondin type-1 motifs 13 |
- |
- |
- |
- |
1件: 64 |
47 |
Rituximab |
Rituximab |
D02994 |
1件: MS4A1 |
1件: Hematopoietic cell lineage |
42件: 11, 13, 14, 17, 35, 36, 43, 44, 45, 46, 49, 50, 51, 52, 53, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 223, 229, 256, 271, 283, 284, 285, 288, 300, 331 |
48 |
Shp655 |
- |
- |
- |
- |
1件: 64 |
49 |
Standard of care |
- |
- |
- |
- |
8件: 6, 13, 14, 49, 51, 64, 79, 85 |
50 |
Standard plasma |
- |
- |
- |
- |
1件: 64 |
51 |
Standrd of care treatment |
- |
- |
- |
- |
1件: 64 |
52 |
Sulfate |
Sulfate ion |
- |
- |
- |
22件: 2, 6, 11, 13, 26, 34, 36, 46, 49, 60, 61, 64, 66, 79, 86, 96, 222, 226, 265, 296, 297, 299 |
53 |
Sulfate, magnesium |
Magnesium |
- |
- |
- |
1件: 64 |
54 |
Uniplas |
- |
- |
- |
- |
1件: 64 |
55 |
Von willebrand factor |
Von willebrand factor human |
- |
- |
- |
2件: 64, 288 |